CLINICAL TRIAL article
Front. Cardiovasc. Med.
Sec. Coronary Artery Disease
Volume 12 - 2025 | doi: 10.3389/fcvm.2025.1638967
This article is part of the Research TopicNovel Role and Mechanisms of Inflammation in Myocardial InfarctionView all 5 articles
Effects of Intensive Rosuvastatin on Ventricular Remodeling and Cardiac Function in Older Patients with STEMI Undergoing PCI
Provisionally accepted
- Qingpu Branch of Zhongshan Hospital Affiliated to Fudan University, Shanghai, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Acute myocardial infarction in the older people often leads to significant left ventricular structural remodeling, which adversely affects prognosis. This study aims to evaluate the effects of intensive rosuvastatin therapy on markers of ventricular remodeling and cardiac function following percutaneous coronary intervention (PCI) in older patients with ST-segment elevation myocardial infarction (STEMI).Methods: This study enrolled 100 patients aged ≥ 60 years with STEMI who underwent emergency PCI. The patients were randomly assigned to either an intensive therapy group (n = 50), receiving rosuvastatin 20 mg/day, or a control group (n = 50), receiving 10 mg/day. Differences in lipid profiles, serum inflammatory markers, fibrosis indicators, and echocardiographic parameters were compared between the two groups before treatment and after 8 weeks of therapy.Results: After 8 weeks of treatment, the intensive group showed significantly reduced serum inflammatory levels compared to the control group, including C-reactive protein (CRP), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and intercellular adhesion molecule-1 (ICAM-1) (P < 0.05). Markers of ventricular remodeling also improved in the intensive group, with lower levels of Nterminal pro-B-type natriuretic peptide (NT-proBNP), galectin-3, and matrix metalloproteinase-9 (MMP-9) compared to the control group (P < 0.05), while levels of tissue inhibitor of metalloproteinases-4 (TIMP-4) were significantly higher (P < 0.05). Additionally, after treatment, the intensive group demonstrated significantly higher levels of left ventricular ejection fraction (LVEF), stroke volume, and peak systolic velocity at the lateral mitral annulus (TDI s'-l) compared to the control group (P < 0.05). Conversely, the left ventricular end-systolic diameter (LVESD) and left ventricular end-systolic volume (LVESV) were significantly lower in the intensive group than in the control group (P < 0.05).In older patients with STEMI, high-dose rosuvastatin demonstrates superior therapeutic efficacy compared to conventional-dose therapy in alleviating inflammatory responses, improving ventricular remodeling, and enhancing cardiac function.
Keywords: Rosuvastatin, ST-segment elevation myocardial infarction, inflammatory cytokines, Ventricular Remodeling, cardiac function
Received: 31 May 2025; Accepted: 06 Aug 2025.
Copyright: © 2025 Qin, Jin, Sun, Luo and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Rong Luo, Qingpu Branch of Zhongshan Hospital Affiliated to Fudan University, Shanghai, China
Haibo Liu, Qingpu Branch of Zhongshan Hospital Affiliated to Fudan University, Shanghai, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.